LIPIDOMICS SHARED RESOURCE GROUP

脂肪组学共享资源的使命是提供先进的方法学、最先进的 为霍林斯癌症中心(HCC)以经济高效的方式合成和分析生物活性脂肪的设施和专业知识。这种共享资源还促进了研究人员、其他共享设施和项目之间的互动，以及与国内和国际其他癌症研究小组的互动。在总监Besim Ogretman博士和运营总监Alicja Bielawska的领导下，脂质组学共享资源代表着一项独特的科学服务，用于测量生物活性脂质分子，特别关注它们在癌症中的作用。 脂肪组学共享资源的目的是： *提供合成脂类、类似物和脂类新陈代谢抑制剂，重点是鞘脂。 *提供来自生物材料的脂类成分的定性和定量分析 列出了300多种不同的分子物种。 *通过提供脂类数据库，改进和开发扩展脂类分析的新技术 正常和转化的细胞和细胞器的组成，这将允许脂质组学方法 对它们的细胞代谢进行分析。 *开发尖端合成分子工具，研究生物活性脂质作为新潜力的作用 抗癌剂。 *开发用于翻译研究的先导化合物。脂肪组学共享资源库的合成脂类、衍生物和相关分子目前超过600种化合物，其中几种正在成为鞘磷脂代谢酶的重要抑制剂，并正在进行临床试验。 *教育和协助癌症委员会调查人员设计和开展旨在 生物活性脂类及其代谢、定量和功能的研究。 在目前的CCSG项目期间，脂质组学共享资源支持了17名肝细胞癌研究人员发表了103篇论文的研究。在项目期间，它支持了MUSC的19笔个人癌症赠款，以及NIH生物医学卓越研究中心(COBRE)在脂质组学和病理生物学方面的资助(P20 RR017677,2002-2012；P30 GM103339,2012-2017)。

The mission of the Lipidomics Shared Resource is to provide advanced methodology, state-of-the-art facilities, and expertise for both synthesis and analysis of bioactive lipids in a cost-effective manner for the Hollings Cancer Center (HCC). This shared resource also facilitates interactions among investigators, other shared facilities, and programs within the HCC as well as with other cancer research groups nationally and internationally. Under the leadership of Drs. Besim Ogretmen, Director, and Alicja Bielawska, Operations Director, the Lipidomics Shared Resource represents a unique scientific service for the measurement of bioactive lipid molecules with a particular focus on their role in cancers. The purposes of the Lipidomics Shared Resource are to: * Provide synthetic lipids, analogs, and inhibitors of lipid metabolism with an emphasis on sphingolipids. * Provide qualitative and quantitative analysis of lipid composition from biological materials with a current listing of more than 300 distinct molecular species. * Improve and develop new techniques for extended lipid analyses by providing a database of the lipid composition of normal and transformed cells and organelles that will permit a lipidomics approach to analysis of their cellular metabolism. * Develop cutting-edge synthetic molecular tools to study the role of bioactive lipids as new potential anticancer agents. * Develop lead compounds for translational studies. The Lipidomics Shared Resource's library of synthetic lipids, derivatives, and related molecules currently exceeds 600 compounds, several of which are emerging as Important inhibitors of enzymes of sphingolipid metabolism and being tested in clinical trials. * Educate and assist HCC investigators in designing and conducting experimental approaches aimed at the study of bioactive lipids, their metabolism, quantitation, and function. During the current CCSG project period, the Lipidomics Shared Resource has supported research that has resulted in 103 publications by 17 HCC investigators. It has supported 19 individual cancer grants at MUSC during the project period and an NIH Center of Biomedical Research Excellence (COBRE) in Lipidomics & Pathobiology (P20 RR017677, 2002-2012; P30 GM103339, 2012-2017).